Figure 1. End-point assays of compounds tested.
(A) Chemical representation of Δ9-trans-tetrahydrocannabinol (THC), cannabidiol-dimethylheptyl (CBD-DMH), 9(R)-Δ6a,10a-THC (6a10aTHC), JWH018, tetrahydrocannabinolic acid, 2-arachidonoylglycerol, cannabidiol (CBD), and anandamide. (B, C) End-point assay for (B) ATX-β and (C) ATX-ɣ inhibition with various cannabinoids and endocannabinoids. All error bars represent the SEM (n = 3). (B, C) Activity rate of 99 and 65 mMol end product/mM ATX/min has been found for (B, C), respectively. ANOVA comparison between CTRL and other conditions showed statistically significant differences for THC, 6a10aTHC, tetrahydrocannabinolic acid, CBD, and 5-DMH-CBD for ATX-β and ATX-γ inhibition (P < 0.005). ATX was not significantly inhibited by JWH018, anandamide, and 2-arachidonoylglycerol (P > 0.005).